Immediate Skin-To-Skin Care For Preterm Infants After Birth
Launched by MEDICAL UNIVERSITY OF GRAZ · Jan 20, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the benefits of immediate skin-to-skin contact for preterm babies right after they are born. Skin-to-skin care, which means holding your baby against your skin, can help both the baby and the mother in many ways. In this study, researchers want to see if starting this contact immediately after birth is safe and effective for babies born between 26 and 32 weeks of gestation (meaning how far along the pregnancy is).
To participate in this trial, parents need to give written consent, and their baby must be born within the specified gestational age. It’s important to note that babies who need full life support or have serious birth defects will not be included in the study. If eligible, families can expect to help researchers understand how this early skin-to-skin time can benefit their newborn, potentially leading to better outcomes for preterm infants in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Gestational age between 26+0 and 32+0 weeks
- • Written parental informed consent
- Exclusion Criteria:
- • No intention of full life support
- • Severe congenital malformation
About Medical University Of Graz
The Medical University of Graz, a leading institution in Austria, is dedicated to advancing medical knowledge and improving patient care through innovative research and clinical trials. Renowned for its interdisciplinary approach, the university collaborates with various healthcare professionals and researchers to explore cutting-edge therapies and treatments. With a commitment to ethical standards and patient safety, the Medical University of Graz actively contributes to the global medical community by facilitating rigorous clinical trials that aim to translate scientific discoveries into practical applications for improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Graz, Styria, Austria
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported